Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below 200 Day Moving Average – What’s Next?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.68 and traded as low as $0.52. Bolt Biotherapeutics shares last traded at $0.53, with a volume of 318,097 shares.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, November 13th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $3.50.

Bolt Biotherapeutics Stock Performance

The business’s fifty day moving average price is $0.62 and its 200-day moving average price is $0.67. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. The stock has a market capitalization of $20.20 million, a PE ratio of -0.31 and a beta of 0.93.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. The firm had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $1.02 million. As a group, equities research analysts expect that Bolt Biotherapeutics, Inc. will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BOLT. Acuitas Investments LLC boosted its position in shares of Bolt Biotherapeutics by 21.7% during the 2nd quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after acquiring an additional 112,555 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in Bolt Biotherapeutics during the second quarter valued at approximately $26,000. Finally, FMR LLC grew its stake in Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after buying an additional 28,773 shares in the last quarter. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.